Akili's Endeavor Market Sales Potential and Endeavor Commercialization Plans

PHILADELPHIA - June 29, 2020 - PRLog -- FDA made a landmark move in the emerging digital therapeutics sector permitting the marketing of First Game-Based Digital Therapeutic Akili's EndeavorRx for ADHD on 15th of June.  We, Mellalta Meets have gathered all findings, one needs to know about this first ever Game-Based Digital Therapeutic with the help of our Marketing intelligence team.

Endeavor is the only game-based device which is now the First Game-Based Digital Therapeutic by Akili Interactive approved to Improve Attention Function in Children with ADHD. The prescription to only game-based device, called Endeavor, is indicated for pediatric patients aging 8 to 12 years old with primarily inattentive or combined-type ADHD who have demonstrated an attention issue.

Akili's Endeavor Study Results in Attention deficit hyperactivity disorder (ADHD)

The Endeavor research program includes three studies on ADHD (STARS-ADHD, STARS-Adjunct and ADHD-POC) together with two pilot studies on ADHD with different comorbidities (Sensory processing disorder and Autism spectrum disorder).

After four weeks, one third of children no longer had a measurable attention deficit on at least one measure of objective attention. In addition, about half of the parents saw a clinically significant change in their child's daily impairments.

Akili's Endeavor Price (currently at no cost)

While one session of cognitive behavioral therapy can cost a patient under $100 per hour, Akili's easily downloadable games will be free or come at an incredibly low cost, depending on their insurance plan. On April 2020, Akili announced that the Endeavor Digital Attention Treatment is available for children with attention deficit hyperactivity disorder (ADHD) under FDA's COVID-19 enforcement discretion guidance at no cost.

Akili's Endeavor Market Sales Potential and Endeavor

Mellalta Meets is quite optimistic about Endeavor's sales potential. In a research note, analysts at the investment bank Jefferies forecast Endeavor's peak sales at $300 million in the United States alone.

Endeavor Competitors

Akili Interactive isn't the only one who has stepped into the digital therapeutic area of ADHD. Barcelona-based Braingaze also announced plans to launch its ADHD therapy app in the Chinese market, while another company called ATENTIV has worked to test its ADHD intervention in Singapore and the United States. Mightier, a member of the Boston Children's Hospital, also raised money from investors for his biofeedback video games designed to help children with emotional adjustment.

"Once it is FDA-approved, then we will be moving to market with a treatment that will be hopefully be prescribed by doctors, either in place of stimulants, or alongside them," Adam Gazzaley's says.

Submit your Request for Proposals at bd@mellalta.com

https://mellalta.com/akilis-game-based-device-endeavor-market-sales-in-attention-deficit-hyperactivity-disorder-adhd/